Microbiome Therapeutics

OverviewSuggest Edit

MicroBiome Therapeutics, LLC, a biotechnology company, develops medical food and pharmaceutical products. The company focuses on developing evidence-based microbiome modulators, which are designed to alter bacteria populations and their environment in the gastrointestinal tract in specific ways to treat and prevent serious health conditions. Its product includes NM504, which contains a combination of prebiotic and other naturally occurring ingredients formulated to help diabetic individuals achieve healthy blood glucose levels and manage their body weight. MicroBiome Therapeutics, LLC was formerly known as NuMe Health LLC. The company was founded in 2009 and is based in Broomfield, Colorado.
TypePrivate
Founded2009
HQNew Orleans, LA, US
Websitembiome.com

Latest Updates

Employees (est.) (Jun 2021)2
Cybersecurity ratingAMore

Key People/Management at Microbiome Therapeutics

John B. Elstrott

John B. Elstrott

Chairman and Co-founder
Dale R. Pfost

Dale R. Pfost

Director, Co-founder and CEO
Ross Barrett

Ross Barrett

Director
Mark Heiman

Mark Heiman

Vice President of Research & Chief Scientific Officer
Paul D. Cordes

Paul D. Cordes

Director
Donald R. Marvin

Donald R. Marvin

Director
Show more

Microbiome Therapeutics Office Locations

Microbiome Therapeutics has an office in New Orleans
New Orleans, LA, US (HQ)
5500 Prytania St #530
Show all (1)

Microbiome Therapeutics Financials and Metrics

Summary Metrics

Founding Date

2009

Microbiome Therapeutics total Funding

$1.3 m

Microbiome Therapeutics latest funding size

$743.45 k

Time since last funding

6 years ago

Microbiome Therapeutics investors

Microbiome Therapeutics's latest funding round in June 2015 was reported to be $743.5 k. In total, Microbiome Therapeutics has raised $1.3 m
Show all financial metrics

Microbiome Therapeutics Cybersecurity Score

Cybersecurity ratingPremium dataset

A

98/100

SecurityScorecard logo

Microbiome Therapeutics Online and Social Media Presence

Embed Graph

Microbiome Therapeutics News and Updates

Human Microbiome Therapeutics Market Report 2021-2031

Forecasts by Technology (Genomics, Proteomics, Metabolomics), by Therapeutic Area (Neurological Disorders, Dermatological Indications, Cancers, Metabolic Disorders, Gastrointestinal Disorders, Other Therapeutic Areas), by Type (Faecal Microbiota Transplantation (FMT), Microbiome Drugs, Microbiome Re…

Human Microbiome Therapeutics Market Size Worth USD 1,098.4 Million by 2027 | Rising Government Initiatives In Microbiome Research Projects And Increasing Drug-Related Side Effects Are Driving The Industry Growth, says Emergen Research

Key participants in human microbiome therapeutics market include Oxidien Pharmaceuticals, LLC, BiomX Ltd., LNC Therapeutics SA, Commense Inc, Embion Technologies SA, DermBiont, Inc, CoreBiome, Inc., Carbiotix AB, Biotagenics Inc., and Finch Therapeutics, among others. Key participants in human micro…

Global Microbiome Therapeutics Markets, 2019-2020 & 2030: Focus on Target Therapies - Gastrointestinal and Infectious Diseases, and Other Diseases

Dublin, Jan. 08, 2021 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030" report has been added to ResearchAndMarkets.com's offering.

Top 10 Companies in the Global Microbiome Therapeutics Market

Dublin, Dec. 29, 2020 (GLOBE NEWSWIRE) -- The "Global Microbiome Therapeutics Market 2020: A Benchmark of the Top 10 Companies" report has been added to ResearchAndMarkets.com's offering. This report profiles companies actively involved in developing microbiome therapeutics.

Global Microbiome Therapeutics Market: Focus on Target Therapies, Region (10 Countries), and Competitive Landscape - Analysis and Forecast, 2019-2030

Global Microbiome Therapeutics Market to Reach $3. 9 Billion by 2030. Market Report Coverage - Microbiome Therapeutics. Market Segmentation Global Microbiome Therapeutics Market to Reach $3. 9 Billion by 2030. Market Report Coverage - Microbiome Therapeutics. Market Segmentation

Frost Radar™: Microbiome Therapeutics, 2020

Microbiome present in the human body has a major role to play in the overall functioning of the human body. Human microbiota consists of a diverse population of bacterial, viral and eukaryotic communities and is present on skin, nasopharynx, oral cavity, respiratory tract, gastrointestinal tract and…
Show more

Microbiome Therapeutics Frequently Asked Questions

  • When was Microbiome Therapeutics founded?

    Microbiome Therapeutics was founded in 2009.

  • Who are Microbiome Therapeutics key executives?

    Microbiome Therapeutics's key executives are John B. Elstrott, Dale R. Pfost and Ross Barrett.

  • How many employees does Microbiome Therapeutics have?

    Microbiome Therapeutics has 2 employees.

  • Who are Microbiome Therapeutics competitors?

    Competitors of Microbiome Therapeutics include Holobiome, Travecta Therapeutics and Nocion Therapeutics.

  • Where is Microbiome Therapeutics headquarters?

    Microbiome Therapeutics headquarters is located at 5500 Prytania St #530, New Orleans.

  • Where are Microbiome Therapeutics offices?

    Microbiome Therapeutics has an office in New Orleans.

  • How many offices does Microbiome Therapeutics have?

    Microbiome Therapeutics has 1 office.